Is Lp(a) largely genetically determined and linked to higher coronary risk?

Lipoprotein(a) [Lp(a)] is an independent, causal risk factor for cardiovascular disease. Because its circulating concentration is largely determined at birth, understanding its genetic architecture and molecular structure is critical for assessing lifelong cardiovascular risk.

Pathogenic mechanisms

• Particle structure: Lp(a) consists of a low-density lipoprotein (LDL)-like core containing a single apolipoprotein B-100 (apoB-100) molecule covalently bound to a highly glycosylated apolipoprotein(a) [apo(a)] tail.
• Atherothrombotic properties: Beyond standard LDL-mediated lipid deposition, Lp(a) promotes vascular damage because it is highly enriched in oxidized phospholipids (OxPL) and shares structural homology with plasminogen, leading to localized inflammation and antifibrinolytic activity.
• Clinical risk: Plasma concentrations exceeding 50 mg/dL are associated with a 1.3- to 2.0-fold increase in cardiovascular event rates.

Genetic drivers and coronary risk

• Heritability: Approximately 70% to over 90% of the variation in plasma Lp(a) is genetically determined, primarily driven by the LPA locus and Kringle IV type 2 (KIV-2) copy number variations.
• The rs3798220 variant: In populations of European ancestry, carrying the heterozygous LPA rs3798220 CT genotype drives a 5- to 10-fold increase in circulating Lp(a) concentrations compared to non-carriers.
• Coronary impact: Carriers of this minor C risk allele experience a 1.5- to 2.0-fold increase in risk for coronary artery disease and coronary heart disease, translating to an approximate doubling of the rate of major adverse cardiovascular events.

Bottom line

• The LPA rs3798220 CT genotype acts as a potent driver of coronary risk (OR 1.5 to 2.0) by causing a 5- to 10-fold elevation in circulating Lp(a), an highly heritable particle that accelerates vascular disease via its dual atherogenic and pro-inflammatory properties.